Neoadjuvant pembrolizumab followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small cell lung cancer (KEYNOTE-671): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2024, accepted for publication.
Ìý
Comparing immediate postoperative outcomes of different VATS approaches for anatomical lung resection: a single-centre retrospective study
Ìý
Ìý
Ìý
Single-cell spatial landscapes of the lung tumour immune microenvironment
Ìý
Ìý
Ìý
Nunavimmi puvakkut kaggutimik aanniaqarniq: Qanuilirqitaa? Lung cancer in Nunavik: How are we doing? A retrospective matched cohort study
Ìý
Ìý
Ìý
Ìý
